Fennec Q3 2026: Net Product Sales Up 56% to $19.4M, Net Income $4.6M
FENC sits 93% above its 52-week low of $5.65.
Summary
Fennec reported Q3 2026 net product sales of $19.4 million (up 56%) and net income of $4.6 million, with cash rising to $48.7 million. The quarter confirms profitable growth, though selling and marketing costs climbed to $10.1 million to support the expanded sales force.
Key Events · Earnings and Guidance · FENC
-
Q3 Net Product Sales Up 56%
PEDMARK net product sales were $19,425K in Q3 2026 versus $12,462K a year earlier, a $6,963K increase; nine-month sales reached $51,697K, up 67% from $30,865K.
-
Company Swings to Profit
Net income was $4,640K ($0.13 basic, $0.12 diluted) versus a $638K net loss in Q3 2025; nine-month net income was $6,814K and Adjusted EBITDA was $5,826K for the quarter.
-
Cash Grows to $48.7 Million
Cash and cash equivalents rose to $48,684K from $36,788K at December 31, 2025, helped by $9,111K of operating cash flow; management says this funds the operating plan for at least twelve months.
-
Commercial Spend Jumps
Selling and marketing expense rose to $10,050K from $6,513K on higher commercial headcount, while G&A fell to $3,912K from $5,449K after the Cipla patent litigation concluded.
Analysis · FENC · Life Sciences
The commercial ramp is now translating into real profit: net product sales of $19.4 million rose 56% year over year, operating income swung to $4.7 million from a small loss, and net income reached $4.6 million ($0.13 per basic share). Cash grew to $48.7 million from $36.8 million at year-end on $9.1 million of operating cash flow, and management says existing cash plus expected revenue funds the plan for at least twelve months. The trade-off is spending: selling and marketing jumped to $10.1 million from $6.5 million as the sales force was expanded, so the growth is being bought with higher commercial costs. New 10b5-1 selling plans for the CFO and a director are also disclosed, routine pre-planned activity rather than a change in the business.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FENC was trading at $10.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $382.2M. The 52-week trading range was $5.65 to $13.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.